Skip to content

Glaxo Gains FDA Clearance for First HIV Prevention Injection

  • Injection is given every two months instead of daily pills
  • Approval boosts Glaxo pipeline with key drug going off-patent

GlaxoSmithKline Plc received U.S. clearance for the first long-acting injection for the prevention of HIV, a significant development for the company as it prepares to split in two next year.

The U.S. Food and Drug Administration approved the drug -- apretude -- for use in adults and adolescents at risk of sexually acquiring HIV, Glaxo said in a statement late Monday. The injection is given as one shot every two months.